Ponatinib versus Bosutinib in 3rd-Line Chronic Phase - Chronic Myeloid Leukemia (CP-CML): Indirect Comparison of Efficacy Using Iterative Proportional Fitting
Open-label trials of ponatinib (PACE, NCT01207440) and bosutinib (NCT00261846; published by Khoury 2012) in third-line patients with CP-CML suggest that ponatinib is more efficacious than bosutinib in this setting, but clinical and reimbursement decisions call for data from head-to-head trials. As such studies are unlikely, we indirectly compared efficacy in the two trials using Iterative Proportional Fitting (IPF) to adjust for differences in baseline characteristics.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Lisa McGarry, Mo Yang, Silvia Chiroli, Stephanie Lustgarten, David Dorer Source Type: research
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Hematology | Leukemia | Lymphoma | Myeloma | Study